# Progress Note 03 — Annual Wellness Visit, Subsequent

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Nelson Mandela (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML021-SYN-TD
- Date: 2001-06-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Thandiwe Mokoena, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Annual Wellness Visit, Subsequent
- Services: HCPCS G0439 (subsequent annual wellness visit) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Subsequent annual wellness visit; no new complaints. **S**

## History of present illness

Mr. Mandela is an 82-year-old man with unfavorable intermediate-risk prostate cancer, seven weeks after his first leuprolide injection, who is due to start radiotherapy in about six weeks. He returns for his subsequent annual wellness visit and completed the health risk assessment beforehand. He finished four weeks of bicalutamide without trouble. Since the injection he has had mild hot flashes, three or four a week, which wake him about once a week; his energy is a little lower in the afternoons, but he still walks every morning. His mood is good and he notices no change in memory or concentration. He has had no breast tenderness, chest pain, breathlessness, or leg swelling. Urinary symptoms are unchanged and mild. He takes vitamin D daily. He has had no falls, emergency visits, or hospital stays in the past year. **S**

| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit |
| Safety events | No falls, emergency visits, or hospital stays in the past year |
| Medicines | Leuprolide 22.5 mg every twelve weeks (second dose due in five weeks); cholecalciferol 1000 units daily; bicalutamide finished four weeks ago |
| Active conditions | Prostate cancer, unfavorable intermediate risk, on androgen deprivation before radiotherapy; low bone mass at the femoral neck |
| Functional status | Independent in all activities and instrumental activities of daily living |

## Health risk assessment

Completed by the patient before the visit and reviewed during the visit. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good |
| Psychosocial | Busy with his foundation and visitors; close family and friends; no loneliness or low mood |
| Tobacco | Never used tobacco |
| Alcohol and drugs | No alcohol (AUDIT-C 0); no other drug use |
| Physical activity | Walks 30 to 45 minutes most mornings; light resistance exercises twice a week added for bone health |
| Nutrition | Regular balanced meals; dairy and leafy greens for calcium; weight up 0.6 kg since starting androgen deprivation |
| Sleep | Seven hours a night; hot flashes wake him about once a week |
| Activities of daily living | Independent |
| Instrumental activities of daily living | Independent; his assistant manages his calendar and he manages his own medicines |
| Home safety | Smoke detectors working; handrails on the stairs; good lighting |
| Falls | No falls this year; no fear of falling |
| Hearing and vision | Some difficulty hearing in crowded rooms; wears glasses; eye examination five months ago |
| Memory | No concerns |
| Pain | Occasional knee stiffness in the morning |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Slightly lower energy in the afternoons on androgen deprivation; weight up 0.6 kg; no fever or night sweats |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Positive | Some difficulty hearing in noisy rooms |
| Cardiovascular | Negative | No chest pain, palpitations, or leg swelling |
| Respiratory | Negative | No cough, breathlessness, or sputum |
| Gastrointestinal | Negative | Bowels regular, about once a day, formed; no bleeding |
| Genitourinary | Positive | Mild urinary frequency, unchanged; no blood in the urine |
| Musculoskeletal | Positive | Mild morning knee stiffness; no bone pain |
| Integumentary | Negative | No new skin lesions |
| Neurological | Negative | No headache, weakness, or numbness |
| Psychiatric | Negative | Mood good; PHQ-2 score 0; no change in memory or concentration |
| Endocrine | Positive | Mild hot flashes three or four times a week on androgen deprivation; no breast tenderness |

12 systems reviewed. **S**

## Current medications

- Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, two doses twelve weeks apart (the second given at a primary care visit), about six months of androgen deprivation with radiotherapy **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/76 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 81 kg; BMI 24.2 kg/m². All vital signs are synthetic.

PHQ-2: 0; Mini-Cog: 5; AUDIT-C: 0. All results are synthetic.

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well, alert, and upright; weight 81.0 kg, BMI 24.2 |
| Eyes | Pupils equal and reactive; near vision 20/30 with glasses |
| Ears | Canals clear; whispered-voice test missed on the left, passed on the right |
| Neck | No thyroid enlargement; no lymph nodes |
| Cardiovascular | Regular rhythm at 68 per minute; no murmur; no ankle swelling |
| Respiratory | Clear to auscultation bilaterally |
| Chest | No gynecomastia or breast tenderness |
| Abdomen | Soft and non-tender |
| Musculoskeletal | Mild crepitus in both knees without effusion; Timed Up and Go 10 seconds; rises from a chair without using his arms |
| Neurological | Alert and oriented; gait steady; Mini-Cog 5 of 5 |
| Psychiatric | Euthymic and engaged; judgment and insight intact |
| Skin | No suspicious lesions |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Subsequent annual wellness visit completed**. Health risk assessment reviewed and a written prevention plan given. Depression, alcohol, cognitive, and fall-risk screens are negative. He misses the whispered voice on the left. The lipid panel at the first visit showed total cholesterol 184, HDL 52, and LDL 112 mg/dL. **S**
   - Audiology for hearing testing.
   - Next annual wellness visit in one year.
2. **Prostate cancer, unfavorable intermediate risk, on androgen deprivation before radiotherapy** (C61). Planned treatment on track: radiotherapy begins in about six weeks, after fiducial markers are placed. **S**
   - Follow-up in five weeks with PSA, testosterone, and vitamin D, and the second leuprolide injection.
3. **Androgen deprivation therapy** (Z79.899). Mild hot flashes and slightly lower afternoon energy, both expected; no treatment wanted. Blood pressure 132/76 mm Hg. Mood and cognition normal. **S**
   - Keep walking and add light resistance exercise, which helps fatigue, muscle, and bone on androgen deprivation.
   - Layered clothing and a cool bedroom for hot flashes; medicines such as venlafaxine are available if they become troublesome.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Pneumococcal vaccine | Completed today | PCV20 given today; no earlier pneumococcal vaccine on record; no further doses needed |
| Recombinant zoster vaccine | Completed today | Dose 1 given today; dose 2 due in two to six months |
| Influenza vaccine | Due | High-dose vaccine when this season's supply arrives in the autumn |
| RSV vaccine | Due | A single dose is recommended at 75 and older; at the pharmacy before the winter |
| COVID-19 vaccine | Due | Recommended at his age with this season's vaccine in the autumn |
| Tetanus, diphtheria, and pertussis booster | Up to date | Tdap seven years ago; next dose due in three years |
| Colorectal cancer screening | Not indicated | Screening from 76 to 85 is selective; discussed, and not recommended for him now, given his age and his current cancer treatment |
| Bone density | Up to date | DXA eight weeks ago before androgen deprivation: femoral neck T-score -1.4, spine -0.6; repeat in one to two years |
| Cholesterol and statin decision | Completed today | Total cholesterol 184, HDL 52, LDL 112 mg/dL at the first visit; no diabetes or smoking. Risk calculators are not validated beyond 79, and evidence for starting a statin for primary prevention after 75 is limited; androgen deprivation adds some cardiometabolic risk. Not started after discussion; lipids and glucose again in one year on the androgen deprivation schedule |
| Lung cancer and abdominal aortic aneurysm screening | Not indicated | Never used tobacco |
| Hepatitis C and HIV screening | Not indicated | Outside the recommended age ranges and no risk factors |
| Depression screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 0 |
| Cognitive assessment | Completed today | Mini-Cog 5 of 5 |
| Falls prevention | Completed today | Timed Up and Go 10 seconds; no falls; walking and resistance exercise continue |
| Hearing | Referred | Whispered-voice test missed on the left; audiology arranged |
| Eye examination | Up to date | Five months ago |

## Advance care planning

Voluntary advance care planning discussion of about 20 minutes, with his consent. He named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is being told the truth about his health, continuing his work for as long as he can, and making his own decisions. He chose not to record specific treatment preferences today. The plan will be revisited yearly and with any change in his health. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026), Aether Forge
- Medicare Wellness Visits (Medicare Learning Network) (2026), Centers for Medicare & Medicaid Services
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Chronic-care follow-up in five weeks with the second leuprolide injection. Radiotherapy to start in about six weeks. Second zoster dose in two to six months. Audiology. Next annual wellness visit in one year. **S**
- Next scheduled visit 2001-07-14: three-month follow-up on androgen deprivation before radiotherapy: PSA, testosterone, vitamin D, and side effects. **S**
